<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ROPINIROLE HYDROCHLORIDE</span><br/>(ro-pi'ni-role)<br/><span class="topboxtradename">Requip<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">anticholinergic (parasympathomimetic)</span>; <span class="classification">antiparkinsonism agent</span><br/><b>Prototype: </b>Levodopa<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.25 mg, 0.5 mg, 1 mg, 2 mg, 5 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Nonergot dopamine receptor agonist structurally similar to pramipexole, for treatment of Parkinson's disease. It has high
         affinity for the D<sub>2</sub> subfamily of dopamine receptors and higher binding affinity to D<sub>3</sub> than to D<sub>2</sub> or D<sub>4</sub> receptor subtypes. The precise mechanism of action is not known.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Indicated by improvement in Parkinson's disease.</p>
<h1><a name="uses">Uses</a></h1>
<p>Idiopathic Parkinson's disease, restless legs syndrome.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ropinirole or pramipexole; lactation, pregnancy (category C).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal and hepatic impairment; concomitant use of CNS depressants. Safety and efficacy in children are not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Parkinson's Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 0.25 mg t.i.d., may titrate up by 0.25 mg/dose t.i.d. qwk to a target dose of 1 mg t.i.d.; if response is still
               not satisfactory, may continue to increase by 1.5 mg/d q wk to a dose of 9 mg/d, and then by <img src="../images/special/lesserorequal.gif"/>3
               mg/d weekly (max: dose of 24 mg/d)<br/><br/><span class="indicationtitle">Restless Legs Syndrome</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Take 0.25 mg 13 h before bed <small>x</small> 2 d, increase to 0.5 mg for the first week, then increase by .05 mg qwk
               to a maximum of 4 mg<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food to reduce occurrence of nausea.</li>
<li>Titrate dose as needed at weekly intervals (see <small>ROUTE &amp; DOSAGE</small>).
         </li>
<li>Discontinue drug gradually over 7 d by decreasing from t.i.d. to b.i.d. dosing for 4 d, and then to q.d. dosing for 3 d.</li>
<li>
            				Note: Lower initial and maintenance doses with moderate-to-severe renal impairment.
            			
         </li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Increased sweating, dry mouth, flushing, asthenia, <span class="speceff-common">fatigue,</span> pain, edema, malaise, <span class="speceff-common">viral infection,</span> UTI, impotence. <span class="typehead">CNS:</span>
<span class="speceff-common">Dizziness, somnolence, sudden sleep attacks</span>, hallucinations, confusion, amnesia, hypesthesia, yawning, hyperkinesia, impaired concentration, vertigo, hallucinations. <span class="typehead">CV:</span>
<span class="speceff-common">Syncope,</span> chest pain, orthostatic symptoms, hypertension, palpitations, atrial fibrillation, extrasystoles, hypotension, tachycardia,
      peripheral edema, peripheral ischemia. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, dyspepsia,</span> abdominal pain, anorexia, flatulence. <span class="typehead">Respiratory:</span> Pharyngitis, rhinitis, sinusitis, bronchitis, dyspnea. <span class="typehead">Special Senses:</span> Abnormal vision, xerophthalmia, eye abnormality. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Ropinirole levels may be increased by <span class="classification">estrogens</span>, <span class="classification">quinolone antibiotics</span>, <b>cimetidine,</b>
<b>diltiazem,</b>
<b>erythromycin,</b>
<b>fluvoxamine,</b>
<b>mexiletine,</b>
<b>tacrine;</b> effects may be antagonized by <span class="classification">phenothiazines</span>, <span class="classification">butyrophenones</span>, <b>metoclopramide.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract; 55% bioavailability. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Distribution:</span> 3040% protein bound. <span class="typehead">Metabolism:</span> Metabolized in the liver by CYP1A2. <span class="typehead">Elimination:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> 6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab test: Periodically monitor BUN and creatinine, hepatic function.</li>
<li>Schedule periodic eye exams and chest x-rays during long-term use.</li>
<li>Monitor carefully for orthostatic hypotension, especially during dose escalation.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware that hallucinations are a possible adverse effect and occur more often in older adults.</li>
<li>Make position changes slowly, especially after long periods of lying or sitting. Postural hypotension is common, especially
            during early treatment.
         </li>
<li>Exercise caution with hazardous activities requiring alertness since drowsiness and sedation are common adverse effects. Effects
            are additive with alcohol or other CNS depressants.
         </li>
<li>Immediately notify physician if you become pregnant.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>